Docebo stock is drawing renewed attention following a reduction in the consensus analyst price target, shifting from CA$55.02 to CA$49.81. This change highlights how shifting perspectives among ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...